Wordt geladen...
Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer
Poly (ADP-ribose) polymerase (PARP) inhibitors are a class of targeted agents for the treatment of solid tumors. Concurrent PARP inhibition in Breast Cancer Susceptibility Gene (BRCA)-mutated or homologous recombination-deficient tumor cells can induce “synthetic lethality”, which targets two DNA re...
Bewaard in:
| Gepubliceerd in: | Cancer Manag Res |
|---|---|
| Hoofdauteurs: | , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Dove
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6519338/ https://ncbi.nlm.nih.gov/pubmed/31191001 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S200524 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|